A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation

Summary

The study is to evaluate the safety and efficacy of COVID-19 convalescent plasma (CCP) transfusion to prevent COVID-19 in adult recipients following hematopoietic stem cell transplantation. 72 patients will be randomized in a 1:1 ratio to receive either CCR (36 patients) or not (36 patients). Patients in the CCP group will receive 200 ml of CCP at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cell transplantation. Patients in the control group would be routinely given oral ursodeoxycholic acid for +14 days after transplantation. The primary goal of the study is to evaluate the safety of CCP and the incidence of COVID-19 infection within +28 days after the last infusion of CCP.

Timeline

Start

2023-06-10

Primary completion

2024-01-01

Completion

2025-01-01

Outcome

Missed primary endpoint

paper These findings indicate that CCP did not prevent COVID-19 infection PMID 41394817 ↗

Publications

• Cao Y, Li Q, Guo W, Xu M, Fang K, Wang F, Zhang R, Li L, Wei J, Liu Z, Liang C, Zhai W, Ma Q, Chen X, Cao W, Yang D, He Y, Pang A, Feng S, Han M, Sun J, Jiang E. Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial. Front Immunol. 2025 Nov 28;16:1626775. doi: 10.3389/fimmu.2025.1626775. eCollection 2025.

Drugs

Indications